Stock Analiz

Yarrow Bioscience, Inc. YARW

Biotechnology: Pharmaceutical Preparations · IPO 2018 · data as of November 13, 2026

$18.03Market cap $207M
Open the interactive analysis →

Yarrow Bioscience, Inc. (YARW) is a healthcare company listed in the US with a market value of about $207M. In the twelve months to June 30, 2026 it had revenue of $482000 and net income of —.

Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -51% a year, a 5-year average ROIC of -70%.

About Yarrow Bioscience

Yarrow Bioscience is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2018. Revenue went from $674000 in 2016 to $570000 in 2025, a decline of about 1.8% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 1242% over three years (dilution for shareholders). It spends 3375% of revenue on research and development.

Score: 1.4 / 5

Value0/5
Future growth3/5
Track record0/5
Financial health4/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S429.2
P/B0.8
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-16.0%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)13.8%
Revenue growth (5 yrs, per year)-51.4%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-6409.9%
ROIC (5-yr avg.)-69.8%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$482000$570000$501000$424000$477000$931000$21M$443000$4M$5M$674000
Net income—-$26M-$40M-$28M-$23M-$73M-$256M-$95M-$74M-$29M-$14M
Free cash flow—-$33M-$34M-$25M—-$56M-$137M-$74M-$69M-$28M-$2M
EPS (diluted)$8.61$-0.62$-0.93$-2.78$-7.28$-25.64$141.86$201.99$206.49$-102.43$-50.77
Net margin—-4646.1%-7950.9%-6710.4%-4865.8%-7876.4%-1217.4%-21484.9%-2062.9%-634.6%-2087.2%
ROIC—-84.7%-66.1%-32.9%-86.8%-78.6%-349.1%-183.9%-64.2%-34.1%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 3 analysts is $57.33, 218% above the current price; targets range from $54.00 to $60.00; the consensus rating is “Strong buy”; expected EPS is $-1.45 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Yarrow Bioscience pay a dividend?

Not currently.

Is Yarrow Bioscience a good stock to buy?

We do not give buy or sell advice. Yarrow Bioscience scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.